Proinflammatory effect of sodium 4-phenylbutyrate in ΔF508-cystic fibrosis transmembrane conductance regulator lung epithelial cells: Involvement of extracellular signal-regulated protein kinase 1/2 and c-Jun-NH 2-terminal kinase signaling

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 3, 2008, Pages 949-956

  Roque, Telma ^a,b   Boncoeur, Emilie ^a,b   Saint Criq, Vinciane ^a,b   Bonvin, Elise ^a,b   Clement, Annick ^a,b,c   Tabary, Olivier ^a,b   Jacquot, Jacky ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 PHENYLBUTYRIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CHLORIDE CHANNEL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEASOME; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA; 4-PHENYLBUTYRIC ACID; ARYLBUTYRIC ACID DERIVATIVE; AUTACOID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508;

ARTICLE; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; HUMAN CELL; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; PRIORITY JOURNAL; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; LUNG; METABOLISM; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA; TOXICITY;

CELL LINE; CELL SURVIVAL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHENYLBUTYRATES; RESPIRATORY MUCOSA;

EID: 53849128192     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.135186     Document Type: Article

References (39)

1. Adcock IM (2007) HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 150:829-831.
2. Adcock IM, Chung KF, Caramori G, and Ito K (2006) Kinase inhibitors and airway inflammation. Eur J Pharmacol 533:118-132.
3. Andersson C and Roomans GM (2000) Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur Respir J 15:937-941.
4. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, et al. (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98:13681-13686.
5. Boncoeur E, Criq VS, Bonvin E, Roque T, Henrion-Caude A, Gruenert DC, Clement A, Jacquot J, and Tabary O (2008) Oxidative stress induces extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase in cystic fibrosis lung epithelial cells: potential mechanism for excessive IL-8 expression. Int J Biochem Cell Biol 40:432-446.
6. Chmiel JF and Davis PB (2003) State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 4:8.
7. Choo-Kang LR and Zeitlin PL (2001) Induction of HSP70 promotes DeltaF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol 281:L58-L68.
8. Farinha CM and Amaral MD (2005) Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol 25: 5242-5252.
9. Gerber A, Heimburg A, Reisenauer A, Wille A, Welte T, and Bühling F (2004) Proteasome inhibitors modulate chemokine production in lung epithelial and monocytic cells. Eur Respir J 24:40-48.
10. Ito K, Charron CE, and Adcock IM (2007) Impact of protein acetylation in inflammatory lung diseases. Pharmacol Ther 116:249-265.
11. Iwata K, Tomita K, Sano H, Fujii Y, Yamasaki A, and Shimizu E (2002) Trichostatin A, a histone deacetylase inhibitor, down-regulates interleukin-12 transcription in SV-40-transformed lung epithelial cells. Cell Immunol 218:26-33.
12. Karin M (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270:16483-16486.
13. Li J, Johnson XD, Iazvovskaia S, Tan A, Lin A, and Hershenson MB (2003) Signaling intermediates required for NF-kappa B activation and IL-8 expression in CF bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 284:L307-L315.
14. Li J, Kartha S, Iasvovskaia S, Tan A, Bhat RK, Manaligod JM, Page K, Brasier AR, and Hershenson MB (2002) Regulation of human airway epithelial cell IL-8 expression by MAP kinases. Am J Physiol Lung Cell Mol Physiol 283:L690-L699.
15. McGrath-Morrow SA and Stahl JL (2000) G(1) Phase growth arrest and induction of p21(Waf1/Cip1/Sdi1) in IB3-1 cells treated with 4-sodium phenylbutyrate. J Pharmacol Exp Ther 294:941-947.
16. Medjane S, Raymond B, Wu Y, and Touqui L (2005) Impact of CFTR DeltaF508 mutation on prostaglandin E2 production and type IIA phospholipase A2 expression by pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 289:L816-L824.
17. Monneret C (2005) Histone deacetylase inhibitors. Eur J Med Chem 40:1-13.
18. Muselet-Charlier C, Roque T, Boncoeur E, Chadelat K, Clement A, Jacquot J, and Tabary O (2007) Enhanced IL-1beta-induced IL-8 production in cystic fibrosis lung epithelial cells is dependent of both mitogen-activated protein kinases and NF-kappaB signaling. Biochem Biophys Res Commun 357:402-407.
19. Place RF, Noonan EJ, and Giardina C (2005) HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol 70:394-406.
20. Prulière-Escabasse V, Planès C, Escudier E, Fanen P, Coste A, and Clerici C (2007) Modulation of epithelial sodium channel trafficking and function by sodium 4-phenylbutyrate in human nasal epithelial cells. J Biol Chem 282:34048-34057.
21. Roebuck KA (1999) Oxidant stress regulation of Il-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB. Int J Mol Med 4:223-230.
22. Rubenstein RC, Egan ME, and Zeitlin PL (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 100:2457-2465.
23. Rubenstein RC and Lyons BM (2001) Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. Am J Physiol Lung Cell Mol Physiol 281:L43-L51.
24. Rubenstein RC and Zeitlin PL (1998) A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 157: 484-490.
25. Singh OV, Vij N, Mogayzel PJ Jr, Jozwik C, Pollard HB, and Zeitlin PL (2006) Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells. J Proteome Res 5:562-571.
26. Sugita M, Kongo H, and Shiba Y (2004) Molecular dissection of the butyrate action revealed the involvement of mitogen-activated protein kinase in cystic fibrosis transmembrane conductance regulator biogenesis. Mol Pharmacol 66:1248-1259.
27. Tabary O, Boncoeur E, de Martin R, Pepperkok R, Clément A, Schultz C, and Jacquot J (2006) Calcium-dependent regulation of NF-(kappa)B activation in cystic fibrosis airway epithelial cells. Cell Signal 18:652-660.
28. Tabary O, Escotte S, Couetil JP, Hubert D, Dusser D, Puchelle E, and Jacquot J (1999) Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells. Am J Pathol 155:473-481.
29. Verhaeghe C, Remouchamps C, Hennuy B, Vanderplasschen A, Chariot A, Tabruyn SP, Oury C, and Bours V (2007) Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem Pharmacol 73:1982-1994.
30. Vij N, Amoako MO, Mazur S, and Zeitlin PL (2008) CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 38:176-184.
31. Vij N, Fang S, and Zeitlin PL (2006) Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem 281:17369-17378.
32. Wade PA (2001) Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 10:693-698.
33. Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H, et al. (2006) Hsp90 cochaperone Aha1 down-regulation rescues misfolding of CFTR in cystic fibrosis. Cell 127:803-815.
34. Weber AJ, Soong G, Bryan R, Saba S, and Prince A (2001) Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function. Am J Physiol Lung Cell Mol Physiol 281:L71-L78.
35. Williams AS, Issa R, Leung SY, Nath P, Ferguson GD, Bennett BL, Adcock IM, and Chung KF (2007) Attenuation of ozone-induced airway inflammation and hyperresponsiveness by c-Jun NH2 terminal kinase inhibitor SP600125. J Pharmacol Exp Ther 322:351-359.
36. Wright JM, Zeitlin PL, Cebotaru L, Guggino SE, and Guggino WB (2004) Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics 16:204-211.
37. Wu HM, Wen HC, and Lin WW (2002) Proteasome inhibitors stimulate interleukin-8 expression via Ras and apoptosis signal-regulating kinase-dependent extracellular signal-related kinase and c-Jun N-terminal kinase activation. Am J Respir Cell Mol Biol 27:234-243.
38. Yin L, Laevsky G, and Giardina C (2001) Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 276:44641-44646.
39. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, and Brass-Ernst L (2002) Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 6:119-126.